CKD Bio Corp. Overview
CKD Bio is the fermentation-API arm of the Chong Kun Dang group, one of Korea's largest pharmaceutical groups. It was carved out of Chong Kun Dang in 2001 and inherited a fermentation heritage dating to the 1960s, including Korea's first US FDA approval (chloramphenicol, 1968).
Its core is a B2B, export-oriented portfolio of fermentation-derived antibiotics, β-lactamase inhibitors, immunosuppressants and antidiabetic APIs, made at a large Ansan plant approved by the FDA, AIFA, PMDA and TGA. Two newer businesses sit on top of this base:
-
a probiotics raw-material and CDMO business, historically anchored by supply to sister company Chong Kun Dang Health's Lactofit brand;
-
a botulinum toxin franchise, Tyemvers (CU-20101 / CKDB-501A), approved in Korea in March 2025, filed in China in August 2026, and in US neuropsychiatric development via partner Healis.
The company is small (FY2025 revenue KRW 160.1B), thinly capitalised (market capitalisation about KRW 74B) and leveraged (net debt about KRW 141B). It sits in a margin squeeze between Indian and Chinese API price competition and an early-stage toxin ramp.
Company's own description. The company describes itself as a developer and producer of high value-added products built on internationally competitive fermentation, synthesis and biotechnology capabilities, backed by continuous R&D (company "CKD BiO" overview page). It describes its Ansan plant in the Banwol industrial complex (51,473 m² site) as supplying the world with antibiotics, β-lactamase inhibitors, antidiabetics and immunosuppressants. The FY2025 annual report summary on FinancialFilings characterises it as a pharmaceutical company specialising in fermentation and chemical synthesis that also produces next-generation probiotics using patented technology.
What it actually does. CKD Bio runs four economic activities:
-
Fermentation and semi-synthetic APIs and intermediates (core; about 83–86% of revenue). Bulk drug substances sold to generic and originator manufacturers worldwide. Key molecules include:
-
potassium clavulanate (β-lactamase inhibitor);
-
rifampicin and rifamycin sodium (anti-tuberculosis);
-
teicoplanin (glycopeptide antibiotic);
-
demeclocycline HCl (DMCT);
-
acarbose (antidiabetic);
-
cyclosporine, tacrolimus and everolimus (immunosuppressants);
-
diquafosol sodium (dry-eye). The company also sells API trading, contract research and contract manufacturing services (product pages, 2026). In 1Q2025, APIs were 85.9% of revenue (KRW 36.5B), and antibiotics alone were 62.1% (KRW 26.4B) (Nate/Bio report, Apr-2026).
-
-
Probiotics (about 13–14% of revenue). Production of probiotic "raw powder" (원말) and finished products. The catalogue lists 25 strains/items, including S. thermophilus, L. bulgaricus, L. rhamnosus, L. reuteri, B. breve and B. longum, at concentrations up to 5×10¹¹ CFU/g (product page). A major historic customer is related party Chong Kun Dang Health (Lactofit). The company also offers microbiome CDMO services.
-
Botulinum toxin type A (about 2% of revenue in 2025–1H2026). Tyemvers 100U, launched in Korea on 21–22 July 2025, with a 200U presentation launched in August 2026. Out-licensing economics come from Cutia Therapeutics (Greater China) and a supply arrangement with Healis Therapeutics (US neuropsychiatry).
-
Contract manufacturing / CDMO. Offered for APIs, intermediates and microbiome products using cGMP fermentation and synthesis assets (company home page).
Revenue model. Revenue is predominantly product sales:
-
B2B bulk API shipments, priced per kilogram under supply contracts and spot orders;
-
B2B probiotic powders;
-
B2C/B2B toxin vials sold to Korean clinics through the company's own sales organisation.
There is small licence and milestone income from toxin partners. For example, the FY2022 toxin-segment revenue of KRW 6.0B is consistent with the Cutia upfront payment plus the China IND milestone (US$2.0M + US$2.5M). There is no subscription revenue.
Value-chain position. Upstream manufacturer of drug substances, sitting between raw-material and nutrient suppliers and finished-dosage formulators. In toxin, the company is vertically integrated from strain to vial.
Customer types and end-markets.
-
Generic and originator drug makers in the US, EU, Japan, emerging markets and Korea. Exports were 79.0% of revenue in 1Q2025 (Medigate, Jun-2025).
-
Health-functional-food brand owners.
-
Korean dermatology and plastic-surgery clinics (toxin).
-
Licensees (Cutia, Healis).
Independent characterisation. CKD Bio is a sub-scale, legacy fermentation-API exporter trying to buy a growth option (toxin) with a balance sheet that has little room for error. The API base provides volume and GMP credibility but is structurally exposed to Indian and Chinese pricing (Kormedi, Apr-2026). Group affiliation (Chong Kun Dang Holdings 39%) provides financing comfort and related-party demand (probiotics), but also governance overlap. The toxin business is differentiated on paper:
-
human-serum-albumin-free (vegan) formulation;
-
GenBank-registered strain of German/European origin;
-
first halal certificate (BPJPH) for a botulinum toxin.
However, it entered as Korea's sixth domestic toxin into a crowded, price-competitive market.
Strategy
Stated strategic themes (company materials and press releases, 2025–2026):
Global probiotics and pharma leadership: The English website states an ambition to become a global leader in probiotics and pharmaceuticals through world-class technology and continuous R&D.
Toxin globalisation on a "clean label" platform: The company positions Tyemvers on strain-origin transparency, an HSA-free vegan process and halal status. It targets Indonesia, the Middle East and Malaysia, and pursues China and the US through partners (press releases, Jul-2025 and Jun-2026). CEO Park framed the 1-year anniversary as a platform to expand domestically and globally (FN News, Jul-2026).
API cost leadership and portfolio refresh: Pipeline additions include diquafosol (dry-eye), an antiviral, an anti-ulcer agent (process validation complete) and several next-generation antibiotics (R&D pipeline page).
Strategic initiatives in the last 24 months (Oct-2024 to Oct-2026):
Medium-term financial targets / guidance: n/d. The company does not publish formal guidance. The only forward-looking commercial target found is the China launch in 2H2027.
Sustainability commitments: ISO 14001 (2022), ISO 45001 (2023) and ISO 37001 anti-bribery (2021) certifications; numeric targets n/d.
Products & Services
API Division — fermentation and synthetic APIs
| Product | Class / application | Key regulatory credentials | Flagship notes | Source |
|---|---|---|---|---|
| Potassium clavulanate | β-lactamase inhibitor, paired with amoxicillin | EDQM CEP (2005); US FDA GMP (2007, 2012); AIFA GMP (2008, 2013) | "World-class Product" (2004); historically the flagship export | Company history |
| Rifampicin | Anti-tuberculosis | US FDA (1985, 2001, 2007, 2012); AIFA (2013); WHO GMP (2013) | Fermentation production since 1980 | Company history |
| Rifamycin sodium | Antibiotic / rifampicin precursor | EDQM CEP (2011); AIFA (2013) | — | Company history |
| Teicoplanin | Glycopeptide antibiotic (MRSA) | EDQM CEP (2011); AIFA (2008, 2013) | — | Company history |
| Demeclocycline HCl (DMCT) | Tetracycline-class antibiotic | US FDA (1991, 2007, 2012) | "World-class Product" (2014) | Company history |
| Acarbose | Antidiabetic (α-glucosidase inhibitor) | EDQM CEP (2008); PMDA (2008); AIFA (2013) | "World-class Product" (2010) | Company history |
| Cyclosporine | Immunosuppressant | EDQM CEP (2009); AIFA (2008, 2013); ANVISA (2012) | "Good Technology of Korea" (1995) | Company history |
| Tacrolimus | Immunosuppressant | — | The company highlights a proprietary purification technology as a next-generation core product | Company overview page |
| Everolimus | Immunosuppressant / anti-cancer | US DMF; EU DMF under development; in-house and EP specifications; 100 g aluminium-can pack | — | Product page |
| Diquafosol sodium | Dry-eye treatment | J-DMF under development; 10 kg fibre-drum pack | Corresponds to pipeline item CKDB-17 (commercialised) | Product page; pipeline |
| Antiviral API (CKDB-103) | Antiviral | — | Pipeline status: production/launch complete | R&D pipeline page |
| Other listed classes (obesity/anti-cancer API; additional antibiotics) | Per website filter categories | — | Individual names not retrievable | Product page |
The company website lists 14 API products across these categories: antibiotics, β-lactamase inhibitors, immunosuppressants, immunosuppressant/anti-cancer, obesity/anti-cancer, dry-eye, antivirals, antidiabetics and anti-tuberculosis. The table below lists every product name confirmed from the company website and history. The remaining website items are not individually retrievable.
Target customers: global generic and originator formulators.
Pricing model: per-kg supply contracts; prices n/d.
Services: API trading, contract research and contract manufacturing (website service tabs).
Probiotics Division
| Item | Description | Source |
|---|---|---|
| Probiotic raw materials (25 items) | Includes Streptococcus thermophilus (4×10¹¹ and 1×10¹¹ CFU/g), Lactobacillus bulgaricus, L. fermentum, L. helveticus, L. salivarius, L. reuteri (1×10¹¹ CFU/g), L. gasseri (1×10¹⁰), L. rhamnosus (5×10¹¹ and 1×10¹¹), Bifidobacterium breve (3×10¹¹ and 1×10¹¹), B. longum (1×10¹¹) | Probiotics product page |
| Lactofit raw powder supply | Core raw powder supplied to Chong Kun Dang Health's Lactofit brand (related party). The company was described as Lactofit's key raw-material supplier in 2019. | DailyPharm (Aug-2019; 2020 article) |
| Finished probiotics | Entry into finished-product exports; companion-animal probiotics also targeted | DailyPharm (company vision article) |
| Microbiome CDMO | Contract development and manufacturing for microbiome products | Company website menu |
| Patented technology | Process technology to improve acid and bile tolerance and gut adhesion | NICE D&B (Jul-2024) |
| Functional ingredient pipeline | CKDB-305 (triglyceride improvement, launched); CKDB-315 (respiratory health, human study complete); CKDB-322 (body fat, human study ongoing); CKDB-314 (glycaemic control, R&D) | R&D pipeline page |
Probiotics revenue history: KRW 2.7B (2017), KRW 5.4B (2018) (DailyPharm, 2019); KRW 15.4B (FY2020), KRW 34.0B (FY2021), KRW 25.0B (FY2022) (S&P Global); KRW 18.2B (9M2024) (Medipana).
Botulinum Toxin Division — Tyemvers (TYEMVERS®; CU-20101; CKDB-501A)
| Attribute | Detail | Source |
|---|---|---|
| Molecule | Clostridium botulinum toxin type A, 100U and 200U | MFDS approval (Mar-2025); 200U launch (Aug-2026) |
| Strain | Exclusively licensed from a European (German) research institute in Jun-2019; registered in NCBI GenBank, which reduces strain-origin litigation risk | DailyPharm (Jan-2022); BioSpectator (Jul-2025) |
| Formulation | Human serum albumin-free, non-animal excipients, vegan process; contains L-histidine | Hankyung (Apr-2025); FN News (Jul-2026) |
| Indication (Korea) | Moderate-to-severe glabellar lines; approved 31-Mar-2025 | DailyPharm (Apr-2025) |
| Korean Phase 3 | 300 patients; randomised, double-blind, active-controlled, multi-centre; non-inferior to onabotulinumtoxinA (Botox); published in Journal of Cosmetic Dermatology (2025) | BioSpectator (Jul-2025) |
| China Phase 3 | 554 patients; non-inferior to Botox; no treatment-related serious adverse events; repeat-dose profile similar to single dose | Bizwatch (Aug-2026) |
| Halal | First botulinum toxin certified by Indonesia's BPJPH (May-2025) | Smart Today (May-2025) |
| Launch | Korea 21/22-Jul-2025 (6th domestic Korean toxin); 200U launch Aug-2026 | Medigate (Jul-2025); Toyo Economy (Jul-2025) |
| Capacity | Osong plant: 6M vials/yr, planned expansion to 16M vials/yr | DailyPharm (Jan-2022) |
| Pricing | — | — |
| Therapeutic pipeline | CKDB-501A therapeutic indications in clinical development (company pipeline); US Phase 1 in major depressive disorder via Healis (IND cleared Jul-2026) | Pipeline page; DailyPharm (Jul-2026) |
| Revenue scale | KRW 0.8B in 1Q2025; about 2% of revenue in 2Q2026 | Nate (Apr-2026); Butler |
Financial Narrative
Income statement (FY2021–FY2025)
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Revenue by Segment and Revenue by Segment (%)
| Segment | FY2020 | FY2021 | FY2022 |
|---|---|---|---|
API division revenue (KRW Bn) | 109.2 | 108.2 | 125.1 |
Probiotics division revenue (KRW Bn) | 15.4 | 34.0 | 25.0 |
Botulinum toxin division revenue (KRW Bn) | 0 | 0 | 6.0 |
Total revenue (KRW Bn) | 124.6 | 142.2 | 156.0 |
API share of revenue (%) | 87.6 | 76.1 | 80.2 |
Probiotics share of revenue (%) | 12.4 | 23.9 | 16.0 |
Segment Margins & Growth (%)
| Segment | FY2021 | FY2022 |
|---|---|---|
API division YoY growth (%) | -0.9 | 15.6 |
Probiotics division YoY growth (%) | 120.3 | -26.6 |
Data Point by Period
| Period | Data point | Source |
|---|---|---|
FY2023 | API group = 83.5% of revenue | NICE D&B technical report (Jul-2024) |
9M2024 | Probiotics revenue KRW 18.2B; probiotics operating profit KRW 2.3B (the only segment profit disclosure found) | Medipana (Jan-2025) |
1Q2025 | API KRW 36.5B (85.9%), of which antibiotics KRW 26.4B (62.1%); toxin KRW 0.8B (≈2%) | Nate/Bio report citing DART (Apr-2026) |
FY2025 | API revenue KRW 113.0B, with overseas share stated as 85% (KRW 110.7B). The two figures are internally inconsistent, since 110.7/113.0 = 98%; treat with caution. | Kormedi (Apr-2026) |
FY2025 | Product mix: antibiotics 71%, probiotics 13%, immunosuppressants 12%, cardiovascular 4% | Jobkorea financial page (2026) |
2Q2026 | API 84%, probiotics 14%, botulinum toxin 2% | Butler (2026) |
Income Statement and Margin Analysis (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Revenue (KRW Bn) | 142.2 | 156.0 | 160.4 | 171.8 | 160.1 |
Revenue growth YoY (%) | 14.2 | 9.7 | 2.8 | 7.1 | -6.8 |
Gross profit (KRW Bn) | 13.3 | 16.8 | 5.0 | 35.9 | 28.8 |
Operating income (KRW Bn) | -11.4 | -14.8 | -20.2 | 11.0 | 3.6 |
Net income (KRW Bn) | -6.6 | -16.7 | -24.2 | 8.7 | -2.9 |
EPS basic = diluted (KRW) | -1,199 | -3,045 | -4,410 | 1,586 | -526 |
Gross margin (%) | 9.4 | 10.8 | 3.1 | 20.9 | 18.0 |
Operating margin (%) | -8.0 | -9.5 | -12.6 | 6.4 | 2.2 |
Net margin (%) | -4.6 | -10.7 | -15.1 | 5.1 | -1.8 |
R&D expense (KRW Bn) | 11.5 | 15.4 | 17.2 | 14.0 | 12.6 |
R&D intensity (% of revenue) | 8.1 | 9.9 | 10.7 | 8.1 | 7.9 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Analysis
| Metric | Period | Value | Source |
|---|---|---|---|
D&A (KRW Bn) | FY2021 / FY2022 / FY2025 | 17.0 / 17.9 / 15.7 | S&P Global; Valueline (FY2025: depreciation 14.64 + amortisation 1.01) |
EBITDA (KRW Bn) | FY2021 / FY2022 / FY2025 | 5.6 / 3.1 / 18.3 | Computed as OI + D&A; FY2025 per Valueline |
EBITDA margin (%) | FY2021 / FY2022 / FY2025 | 3.9 / 2.0 / 11.4 | Computed |
Pre-tax income (KRW Bn) | FY2021 / FY2022 / FY2025 | -13.4 / -18.6 / -3.0 | S&P (pre-tax margin × revenue); Valueline |
Interest expense (KRW Bn) | FY2021 / FY2022 / FY2025 | 1.9 / 2.9 / 5.6 | S&P Global; Valueline |
Dividend per share (KRW) | FY2018 / FY2019 / FY2020 / FY2021 | 190 / 190 / 200 / 100 (FY2018–19 split-adjusted) | S&P Global |
Dividend per share (KRW) | FY2024 | ≈100 (inferred from KRW 0.54B paid in 1H2025 on 5.49M shares) | Valueline cash-flow data |
Dividend per share (KRW) | FY2022, FY2023 | — | — |
Dividend per share (KRW) | FY2025 | No dividend outflow in 1H2026, consistent with no FY2025 dividend | Valueline |
Revenue History
| Quarter | Revenue | Operating income | Net income | Source |
|---|---|---|---|---|
1Q2024 | — | 3.2 | — | DailyPharm (Apr-2024) |
2Q2024 | 51.0 | 5.0 | 4.4 | The Fact (Jul-2024) |
1Q2025 | 42.5 | 2.1 | 0.9 | DART preliminary (25-Apr-2025) |
2Q2025 | 41.2 | 2.9 | -0.5 | DART preliminary (25-Jul-2025) |
3Q2025 | 34.1 | -1.5 | -2.2 | DART preliminary (31-Oct-2025) |
4Q2025 (implied) | 42.3 | ≈0.1 | ≈-1.1 | FY2025 less 9M2025 (computed) |
1Q2026 | 40.7 | -1.7 | -2.0 | DART preliminary (24-Apr-2026) |
2Q2026 | 41.1 | -5.0 | -5.4 | DART preliminary (31-Jul-2026) |
1H2026 cumulative | 81.8 | -6.7 | -7.4 | Kormedi (Aug-2026) |
Balance Sheet
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Total assets (KRW Bn) | 298.5 | 312.6 | 293.8 | 284.5 | 299.9 |
Cash and short-term financial assets (KRW Bn) | 3.5 | 16.7 | 6.3 | 1.2 | 1.5 |
Trade receivables (KRW Bn) | 29.1 | 25.9 | 34.0 | 31.2 | 34.7 |
Inventory (KRW Bn) | 70.4 | 78.5 | 69.1 | 80.5 | 96.8 |
PP&E (KRW Bn) | 191.2 | 179.3 | 170.8 | 158.1 | 153.7 |
Goodwill (KRW Bn) | 0 | 0 | 0 | 0 | 0 |
Intangible assets (KRW Bn) | 2.8 | 3.8 | 6.1 | 6.5 | 5.6 |
Short-term borrowings incl. current portion and bonds due within 1 year (KRW Bn) | 19.3 | 56.3 | 75.8 | 70.1 | 125.6 |
Long-term borrowings and bonds (KRW Bn) | 89.3 | 80.4 | 69.4 | 59.9 | 17.3 |
Total borrowings (KRW Bn) | 108.6 | 136.7 | 145.2 | 130.0 | 142.9 |
Net debt (KRW Bn) | 105.1 | 120.0 | 138.9 | 128.8 | 141.4 |
Total liabilities (KRW Bn) | 137.0 | 164.8 | 170.8 | 153.5 | 172.8 |
Shareholders' equity (KRW Bn) | 161.5 | 147.8 | 123.0 | 131.0 | 127.0 |
Working capital (KRW Bn) | 60.0 | 41.9 | 13.2 | 24.5 | -15.8 |
Cash Flow
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Operating cash flow (KRW Bn) | -5.9 | -3.2 | -7.2 | 14.0 | -4.1 |
Metric | Period | Value (KRW B) | Source | — | — |
Capex (PP&E purchases) | FY2021 / FY2022 / FY2025 | 20.5 / 6.2 / 6.8 | S&P Global; Valueline | — | — |
Free cash flow (OCF − capex) | FY2021 / FY2022 / FY2025 | -26.4 / -9.4 / -10.9 | Computed | — | — |
Capex and FCF | FY2023, FY2024 | — | — | — | — |
Dividends paid | FY2021 / FY2022 / FY2025 | 1.10 / 0.55 / 0.54 | S&P Global; Valueline | — | — |
Share buybacks | FY2021–FY2025 | None (no treasury shares) | Butler; Valueline | — | — |
Capex, earlier peak | FY2019 / FY2020 | 47.3 / 61.7 (Ansan probiotics and Osong toxin plants) | S&P Global | — | — |
Operating cash flow, TTM to 30-Jun-2026 | — | 1.0 | Valueline | — | — |
Capex, TTM to 30-Jun-2026 | — | 10.75 | Valueline | — | — |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Ratio | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
ROE (%; net income / average equity) | -4.0 | -10.8 | -17.9 | 6.9 | -2.2 |
ROA (%; net income / average assets) | -2.3 | -5.5 | -8.0 | 3.0 | -1.0 |
Pre-tax ROIC (%; OI / year-end equity + net debt) | -4.3 | -5.5 | -7.7 | 4.2 | 1.3 |
Current ratio (x) | 2.35 | 1.51 | 1.13 | 1.27 | 0.90 |
Borrowings / equity (x) | 0.67 | 0.92 | 1.18 | 0.99 | 1.13 |
Liabilities / equity (%) | 84.8 | 111.5 | 138.9 | 117.2 | 136.1 |
Asset turnover (x) | 0.49 | 0.51 | 0.53 | 0.59 | 0.55 |
Days inventory outstanding (days) | 199 | 206 | 162 | 216 | 269 |
Days sales outstanding (days) | 75 | 61 | 77 | 66 | 79 |
Days payables outstanding (days) | 28 | 22 | 16 | 16 | 17 |
Cash conversion cycle (days) | 246 | 245 | 223 | 266 | 331 |
Financial Analysis — Net debt / EBITDA
| Ratio | Period | Value | Note |
|---|---|---|---|
Net debt / EBITDA (x) | FY2021 / FY2022 / FY2025 | 18.8 / 38.7 / 7.7 | FY2023–FY2024 EBITDA n/d |
Interest coverage, OI / interest (x) | FY2021 / FY2022 / FY2025 | -5.9 / -5.0 / 0.64 | — |
Net debt / EBITDA, TTM to Jun-2026 (x) | — | ≈13.8 | Net debt KRW 145.8B; EBITDA KRW 10.6B (Valueline TTM) |
EBITDA / interest, TTM to Jun-2026 (x) | — | ≈1.9 | Interest KRW 5.6B |
Measure by Period
| Period | Measure | Value | Source |
|---|---|---|---|
1Q2025 | Export share of revenue | 79.0% (above the 30.6% average for 50 listed Korean pharma companies) | Medigate (Jun-2025) |
TTM to Jun-2025 | Domestic vs export revenue | Domestic KRW 44.0B; export KRW 115.1B (export ≈72%) | DART line items via Valueline |
FY2025 | API overseas share | Stated as 85%, i.e. | Kormedi (Apr-2026) |
2Q2025 | Export mix and toxin share | Exports up YoY, with Korea's API exporters cited as growing on European demand | Medigate (Jun-2025) |
| 2010 | Export milestone | US$100M Export Tower award | Company history; NICE D&B |
Share Price and Market Valuation
| Metric | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
Year-end share price (KRW) | 23,800 | 23,850 | 22,000 | 20,350 |
Year-end market cap (KRW Bn) | 130.6 | 130.8 | 120.7 | 111.6 |
Year-end price-to-book (x) | 0.88 | 1.06 | 0.92 | 0.88 |
Performance Measure Details
| Performance measure | Value | Basis / source |
|---|---|---|
Last price | KRW 13,500 (19-Oct-2026) | Valueline |
YTD 2026 | -33.7% | Computed vs KRW 20,350 at end-2025 |
≈3-year (vs end-2023) | -43.4% | Computed vs KRW 23,850 |
1-year | -40.1% (Paasa snapshot) / -49.2% (Investing.com, 29-Jul-2026) | Third-party snapshots |
5-year | -67.6% | Paasa snapshot (date n/d) |
52-week range | KRW 11,770 – 24,900 (Stockhub, Sep-2026); KRW 12,150 – 27,650 (Investing.com, Jul-2026) | — |
Liquidity | 3-month average volume ≈52.6K shares | Investing.com (Jul-2026) |
Valuation Multiples
| Multiple | CKD Bio | Basis |
|---|---|---|
P/E (TTM) | n/m (loss) | TTM EPS ≈ KRW -1,958 (Valueline) |
P/B | ≈0.62x | BPS KRW 21,795 (30-Jun-2026) |
P/S (TTM) | ≈0.47x | TTM revenue KRW 158.1B (Jun-2026) |
EV (KRW Bn) | ≈219.9 | Market cap 74.1 + net debt 145.8 (Jun-2026) |
EV/Sales (TTM) | ≈1.39x | — |
EV/EBITDA (TTM) | ≈20.8x | TTM EBITDA KRW 10.56B (Valueline) |
Capital Markets
| Item | Status | Source |
|---|---|---|
Analyst consensus | No current sell-side coverage | Simply Wall St |
Historical coverage | Hana Financial (2019–20; BUY, TP KRW 42,100); Daishin (2019–20); Korea IR Council (2022); NICE D&B technical report (2024); iM Securities (2024) | Alphasquare archives |
Dividend policy | Historically about KRW 100–200 per share; FY2021 KRW 100; FY2024 ≈KRW 100 (inferred); FY2025 nil (inferred). Dividend yield shown as 0.49% (Stockhub) / 0.69% (Eulerpool) on trailing data. | S&P; Valueline; Stockhub |
Buyback authorisations | None; no treasury stock | Butler |
Credit ratings (Moody's / S&P / Fitch) | None. No public domestic rating found; bonds of KRW 25.2B (FY2022) and KRW 36.9B (FY2023–FY2024) appear to have been privately placed and were redeemed by 1H2026. | Valueline |
Debt maturity profile (30-Jun-2026) | Due within 1 year: KRW 102.0B (short-term borrowings 96.3 + current portion of long-term debt 5.7). Due after 1 year: KRW 44.4B. Detailed ladder n/d. | Valueline (DART half-year report) |
Analyst Conclusions
Management guidance: none published. The only stated milestone is a China launch in 2H2027, plus an ambition to expand Tyemvers globally (press releases, Aug-2026). Consensus growth expectations: n/d (no coverage).
Bull case
-
China approval re-rates the toxin franchise. A positive NMPA decision (US$1.5M milestone, 5% royalty, 15-year supply) would turn the KRW 45.7B Osong asset from a sunk cost into a cash generator. The plant can scale to 16M vials.
-
API margins revert to FY2024 levels. FY2024 showed that a 20.9% gross margin and an 11% EBITDA-plus margin are achievable on about KRW 170B of revenue. With a 270-day inventory base, any price stabilisation releases working capital quickly.
-
Deep asset discount. At about 0.6x book, with land carried at KRW 58.8B and PP&E of KRW 154B against a KRW 74B market cap, the stock prices in persistent losses. Parent support (39% owner) limits tail risk.
Bear case
-
Structural API price erosion. Indian fermentation leaders (Concord: about 42% EBITDA margin, revenue about 5x CKD Bio's) set the price. CKD Bio's 1H2026 operating loss of KRW 6.7B came despite R&D cuts.
-
Liquidity squeeze. Cash of KRW 0.6B against KRW 102B of current debt, a current ratio below 1x, and EBITDA/interest of about 1.9x. Any lender retrenchment could force a dilutive equity raise; none has been announced.
-
Toxin economics are thin. Revenue is about 2% of sales a year after launch, in a market led by Hugel and Nabota. China royalties at 5% would only start in 2H2027, and the US programme is a partner-funded Phase 1.
Key catalysts and monitorables (next 12 months)
Analyst verdict. CKD Bio is a legacy Korean fermentation-API company carrying a growth option it can barely afford. The core business has genuine assets: decades of FDA, AIFA and PMDA approvals, large fermenter volume at Ansan, and CEPs for globally traded molecules such as potassium clavulanate, cyclosporine and acarbose. The FY2024 turnaround (gross margin up from 3% to 21%, operating profit of KRW 11.0B) shows the plant can earn money when pricing cooperates.
The evidence since then is discouraging. Revenue fell 6.8% in FY2025 and a further 2.3% in 1H2026, and operating profit swung to a KRW 6.7B loss in the half, even though R&D spending was cut by more than a quarter from its FY2023 peak. That pattern points to price-driven erosion from Indian and Chinese competitors, not a temporary cost spike.
The balance sheet is now the binding constraint. Net debt of about KRW 146B against TTM EBITDA of about KRW 11B, near-zero cash, and roughly KRW 100B of debt rolling within twelve months leave CKD Bio dependent on lender goodwill and, implicitly, on Chong Kun Dang Holdings.
Tyemvers is a credible, differentiated product: clean-label, halal, non-inferior to Botox in two Phase 3s, and on file in China. But its economics to CKD Bio are modest in the near term. A 5% Chinese royalty and a US$1.5M milestone do not repair the balance sheet before 2028, and domestic sales remain a rounding error against the API base.
At about 0.6x book and about 21x EV/TTM EBITDA, the equity is a leveraged option on API price stabilisation plus China approval. A sustained recovery requires evidence of positive operating cash flow and inventory release in 2H2026. Absent that, the risk of a dilutive recapitalisation or group-level restructuring outweighs the toxin upside.
Stance: Speculative / high-risk. Monitor 3Q2026 results and debt roll-over before taking a constructive view.
Principal sources consulted
-
DART filings via FinancialFilings (FY2025 annual report, 18-Mar-2026), Valueline/DataHero (FY2022–1H2026 line items), Butler and ETFshopping (disclosure lists and preliminary results)
-
S&P Global Market Intelligence via StockAnalysis (FY2018–FY2022)
-
Paasa (FY2021–FY2025 summary financials)
-
CKD Bio corporate website (overview, history, facilities, GMP, R&D pipeline, product catalogues)
-
Korean trade and financial press: Kormedi (Apr-2026, Aug-2026); DailyPharm (2016–2026); Medigate; Medifonews; Dealsite; Bizwatch; BioSpectator; Smart Today; Toyo Economy; FN News; Asia Economy; Hankyung; Medipana
-
NICE D&B / Korea IR Council technical report (Jul-2024); Korea IR Council report (Sep-2022); Hana Financial and Daishin research (2019–2020)
-
Competitor data: Dealsite and Medifonews (Hugel, Medytox, Daewoong); HDFC Sky and ICRA (Concord Biotech); Alphadistill and DailyPharm (Kyongbo)
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Executive Leadership Team
| Name | Role | Tenure | Prior roles | Education | Age |
|---|---|---|---|---|---|
Park Wan-gap (박완갑) | CEO and representative director | Since 28-Mar-2024 | Kyongbo Pharmaceutical (group affiliate) from 2010 for 14 years in overseas sales and purchasing; head of API sales from 2022 | BS Chemistry and MS Inorganic Chemistry, Hanyang University | — |
Lee Jung-jin (이정진) | Former CEO | From 17-Mar-2017; end date n/d (succeeded by Park, Mar-2024) | Head of Daewoong Pharmaceutical's Bio Research Institute; R&D head at Binex; principal researcher at the Osong medical-industry foundation's new-drug centre | PhD Microbiology, Seoul National University | Born 1964 |
Kang Hee-il (강희일) | Former CEO | Resigned Mar-2017 | — | — | — |
Lee Jung-hee (이정희) | Head of bio division (toxin commercial) | Joined around 2020 | Department head for Daewoong's Nabota toxin business | — | — |
Lee Ju-won (이주원) | Former non-executive director of CKD Bio | Dates n/d | Eldest son of group chairman Lee Jang-han; promoted to managing director (상무) at Chong Kun Dang in Jan-2026; holds 2.89% of CKD Holdings | — | — |
Lee Su-han (이수한) | Non-executive director (re-elected Mar-2017) | Current status n/d | — | — | — |
Kim Young-chan (김영찬) | Outside director (re-elected Mar-2017) | Current status n/d | — | — | — |
Ahn Dong-myung (안동명) | Standing auditor (re-elected Mar-2017 for 3 years) | Current status n/d | — | — | — |
Governance Overview
| Item | Status | Source |
|---|---|---|
Board size and independence ratio | n/d (CKD Bio's asset size is below the KRW 2T threshold that mandates a majority-independent board) | — |
Audit structure | Standing auditor model historically (2017); current structure n/d | DailyPharm (Mar-2017) |
Governance report | Corporate governance report filed 1-Jun-2026 | Butler disclosure list |
Major Shareholders
| Holder | Stake (%) | Date | Source |
|---|---|---|---|
Chong Kun Dang Holdings Corp. | 39.11 | 31-Mar-2024 | 1Q2024 report via NICE D&B |
Lee Bok-hwan (relative of chairman Lee Jang-han) | 0.05 | 31-Mar-2024 | NICE D&B |
Other shareholders | 60.84 | 31-Mar-2024 | NICE D&B |
Historic: CKD Holdings and affiliates | 37.26 / 37.30 / 39.16 | Oct-2019 / Feb-2020 / Jun-2022 | Hana Securities; Korea IR Council |
Foreign ownership (%) | n/d (9.2–9.6% in 2019–2020) | Hana Securities (2019–2020) | — |
Treasury shares | 0 | 2026 | Butler |
Competitive Landscape
Competitors by Segment
| Segment | Competitor | Country | Latest revenue (as reported) | Positioning vs CKD Bio | Source |
|---|---|---|---|---|---|
Fermentation immunosuppressant APIs | Concord Biotech | India | FY2025 (Mar-25) revenue INR 1,200.1 crore; API INR 940.1 crore; EBITDA INR 506.3 crore (42.2% margin) | Scale and cost leader; claims to be the only supplier of a complete fermentation immunosuppressant API portfolio | HDFC Sky; Concord earnings call |
Immunosuppressant / statin APIs | Biocon | India | — | Large-scale fermentation API competitor | — |
Rifampicin / anti-TB APIs | Lupin and Chinese producers | India / China | — | Low-cost anti-TB supply | — |
Clavulanate / β-lactam APIs | Sandoz (Kundl) and Chinese clavulanate producers | Austria / China | — | Integrated β-lactam chains | — |
Korean APIs (group affiliate) | Kyongbo Pharmaceutical | Korea | 2025 revenue KRW 264.1B, operating margin 1.3%; API segment KRW 101.1B (Alphadistill) or KRW 133.8B (DailyPharm) — sources conflict | Synthetic cephalosporin and oncology APIs plus finished products; building ADC CDMO | Alphadistill; DailyPharm (May-2026) |
Korean APIs | Yuhan Chemical; Hanmi Fine Chemical; ST Pharm | Korea | n/d (ST Pharm 3Q25 revenue KRW 81.9B) | Captive or CDMO-oriented API houses | Medigate (Nov-2025) |
Botulinum toxin | Hugel | Korea | 2025 revenue KRW 425.1B; OI KRW 201.6B; toxin KRW 233.8B | Korean market leader; US, China and EU approvals | Dealsite (Feb-2026) |
Botulinum toxin | Daewoong Pharmaceutical (Nabota/Jeuveau) | Korea | Nabota 2025 sales KRW 229.0B | US partner Evolus; about 14% US aesthetic share (2025) | Kormedi (2026); Bizwatch (Jul-2025) |
Botulinum toxin | Medytox | Korea | 2025 revenue KRW 247.3B; OI KRW 17.2B | Premium Coretox, Newlux; also entering probiotics | Medifonews (2026) |
Botulinum toxin | AbbVie (Botox), Ipsen (Dysport), Merz (Xeomin), Huons BioPharma, Jetema | US / FR / DE / KR | — | Global incumbents and domestic challengers | — |
Probiotics | Cell Biotech; Novonesis (Chr. Hansen); IFF; Medytox (MT961) | KR / DK / US | — | Branded strain owners and global ingredient majors | — |
Peer Comparison FY2025
| Metric | CKD Bio (FY2025) | Hugel (FY2025) | Concord Biotech (FY2025, Mar-25) | Kyongbo Pharm. (FY2025) |
|---|---|---|---|---|
Revenue | KRW 160.1B | KRW 425.1B | INR 1,200.1 crore | KRW 264.1B |
Revenue growth YoY | -6.8% | +14.0% | +18.0% | +10.7% |
Operating margin | 2.2% | 47.4% | n/d (EBITDA margin 42.2%) | 1.3% |
R&D intensity | 7.9% | — | — | 6.9% (DailyPharm, reported period) |
Export share | ≈72–79% | Toxin and filler export share 74% | 45% exports (domestic 55%) | — |
Recent Developments
Litigation, regulatory actions, layoffs and hiring in this period:* none material identified. Headcount was 530 at 31-Mar-2026.



